Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100010, China
NCT Number: NCT07803419
This study is a multicenter, prospective, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the safety and potential efficacy of endovascular recanalization strategies in patients with symptomatic non-acute carotid artery occlusion and cognitive impairment. Eligible participants will be randomly assigned to best medical treatment alone, endovascular recanalization without proximal protection plus best medical treatment, or endovascular recanalization with proximal balloon protection plus best medical treatment. The study will assess whether endovascular recanalization improves cognitive function and whether proximal protection reduces procedure-related new ischemic lesions on diffusion-weighted magnetic resonance imaging.
Trial opening soon.
Get Notified18 year–80 year
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100010, China
Symptomatic non-acute carotid artery occlusion may lead to recurrent ischemic events, chronic cerebral hypoperfusion, and cognitive decline. Best medical treatment is the standard foundation of care, but selected patients with persistent hypoperfusion may remain at risk. Endovascular recanalization may improve cerebral perfusion, but procedure-related distal embolization and new ischemic lesions remain important safety concerns.
Eligible patients will have symptomatic non-acute carotid artery occlusion, ipsilateral cerebral hypoperfusion, and baseline cognitive impairment defined by an education-adjusted Montreal Cognitive Assessment score of 25 or lower. Participants will be randomized in a 1:1:1 ratio to best medical treatment alone, endovascular recanalization without proximal protection plus best medical treatment, or endovascular recanalization with proximal balloon protection plus best medical treatment.
In the proximal protection group, a balloon guide catheter will be used to achieve proximal flow arrest or flow control during key procedural steps. In the unprotected endovascular group, recanalization will be performed without routine proximal balloon flow control. The primary safety outcome is the number of new ischemic lesions on diffusion-weighted magnetic resonance imaging within 24 to 72 hours. The primary efficacy outcome is the change in Montreal Cognitive Assessment score from baseline to 6 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
①Head CT perfusion imaging showed low perfusion in the lesion vascular area (CBF decreased by 30% compared with contralateral perfusion)
②ASITN/SIR collateral circulation score based on DSA < 3 points
③Cerebral infarction with hemodynamic abnormalities confirmed by head MRI (such as watershed infarction)
Exclusion criteria
Guideline-based best medical treatment includes antiplatelet therapy and management of vascular risk factors, such as blood pressure, lipid, glucose, and lifestyle management, according to current clinical practice.
Endovascular recanalization will be performed using neurointerventional techniques. A balloon guide catheter will be positioned proximally to achieve temporary flow arrest or flow control during key lesion-treatment steps, with the aim of reducing distal migration of thrombus or plaque debris.
Endovascular recanalization will be performed using standard neurointerventional techniques without routine proximal balloon flow arrest or flow control.
Time frame: 6 months after randomization
Changes of cognitive function (MoCA score) compared with baseline 6 months after randomization
Time frame: Within 24-72h after randomization
Total number of new infarcts on DWI-MRI within 24-72 hours after randomization
Time frame: 24-72 hours after randomization
The volume of new infarcts 24-72 hours after randomization
Time frame: 24-72 hours after randomization
Incidence of new infarcts 24-72 hours after randomization
Time frame: 24-72 hours after randomization
Distribution characteristics of new infarcts 24-72 hours after randomization (within or beyond the scope of responsible vessels)
Time frame: 24-72 hours after randomization
location of new infarcts 24-72 hours after randomization (only cortical area, only deep white matter area, cortex and white matter were involved)
Time frame: 24-72 hours after randomization
The average number of new infarcts per enrolled patient 24-72 hours after randomization
Time frame: 24-72 hours after randomization
The average number of new infarcts in the responsible vessels of each enrolled patient 24-72 hours after randomization
Time frame: 24-72 hours after randomization
The average number of new infarcts beyond the scope of responsible vessels per enrolled patient 24-72 hours after randomization
Time frame: Within 72 hours after randomization
The rate of symptomatic intracranial hemorrhage (SICH) within 72 hours after randomization (Heidelberg bleeding classification)
Time frame: Within 72 hours after randomization
Operation related complications within 72 hours after randomization (operation related complications, defined as arterial dissection, new area embolism, cavernous sinus fistula, arterial perforation, subarachnoid hemorrhage, etc.)
Time frame: Within 30 days after randomization
Any stroke (hemorrhagic or ischemic) or death within 30 days after randomization
Time frame: Within 6 months after randomization
Occurrence of recurrent ischemic stroke (symptomatic ischemic cerebral infarction or TIA) of responsible vessels within 6 months after randomization
Time frame: 6 months after randomization
Restenosis or re-occlusion of target vessels confirmed by CTA/DSA 6 months after randomization
Time frame: 6 months after randomization
The changes of cognitive function (MMSE score) compared with baseline 6 months after randomization
Time frame: 6 months after randomization
mRS score 6 months after randomization
Time frame: 6 months after randomization
Changes in fundus blood vessels and fundus structures 6 months after randomization (average thickness of retinal nerve fiber layer around optic disc and average thickness of macular ganglion cell complex/ganglion cell-inner plexus layer
Time frame: Within 12 months after randomization
Occurrence of recurrent ischemic stroke (symptomatic ischemic cerebral infarction or TIA) of responsible vessels within 12 months after randomization
Time frame: 12 months after randomization
Restenosis or reocclusion of target vessels confirmed by CTA/DSA 12 months after randomization
Time frame: 12 months after randomization
The MMSE score changes compared with baseline 12 months after randomization
Time frame: 12 months after randomization
MoCA score changes compared with baseline 12 months after randomization
Time frame: 12 months after randomization
Changes in fundus blood vessels and fundus structures 12 months after randomization (average thickness of retinal nerve fiber layer around optic disc and average thickness of macular ganglion cell complex/ganglion cell-inner plexus layer)
Contact information is provided by the study sponsor or research team.
Dapeng Mo
Other
Endovascular Treatment for Symptomatic Non-acute Carotid Occlusion - A Multicenter, Prospective, Blind Endpoint, Pilot, Randomized Controlled Trial
Acronym: ASCENT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06303414
Non-acute Carotid Artery Occlusion
Beijing, Beijing Municipality, China
View Trial DetailsNCT07200739
Alzheimer Dementia (AD), Alzheimer Disease
Roskilde, Region Sjælland, Denmark
View Trial DetailsNCT07435220
Cognition Disorders, Cognitive Dysfunction
View Trial DetailsNCT07788755
Cognition Disorders, Cognitive Dysfunction
Minneapolis, Minnesota, United States
View Trial Details